SCHEMBL4921141

SCHEMBL4921141

CCCCOc1[c]nns1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.37
CYP2D6 P10635 5/20 0.37
CYP3A4 P08684 3/20 0.37
CYP2C9 P11712 5/20 0.34
CYP2C19 P33261 5/20 0.34
CYP19A1 P11511 4/20 0.34
CHRM1 P11229 1/20 0.34
LTA4H P09960 3/20 0.32
RAB9A P51151 3/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
NR5A1 Q13285 1/20 0.32
HTR1D P28221 1/20 0.31
HTR1B P28222 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31
NPC1 O15118 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922788 0.88
SCHEMBL4922565 0.63 CYP19A1 (0.41) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL9869101 0.61 CYP1A2 (0.37) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL4924568 0.61 CYP2D6 (0.38) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL10692851 0.61 LTA4H (0.46) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL30605677 0.61 LTA4H (0.46) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL598441 0.60 CYP2D6 (0.43) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL3011707 0.60 LTA4H (0.41) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL14267190 0.60 CYP2D6 (0.39) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL919712 0.59 RAB9A (0.36) CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PFIZER INC. 2008-08-21 US disclosed
EP-1866317-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-19 EP disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PF4, TBXA2R, P2RY4 CYP1A2 578/4885CYP2D6 113/4885CYP3A4 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.